<DOC>
	<DOCNO>NCT01697410</DOCNO>
	<brief_summary>The purpose study evaluate efficacy terlipressin treat septic shock .</brief_summary>
	<brief_title>Continuos Terlipressin Infusion Septic Shock</brief_title>
	<detailed_description>Septic shock common cause death intensive care unit mortality rate 40 60 % .Vasopressin commonly use adjunct catecholamine support blood pressure refractory septic shock.Recently small sample clinical study suggest Terlipressin , vasopressin analogue , effective reverse sepsis-induced arterial hypotension reduce norepinephrine requirements.But effect mortality unknown.Invesgators hypothesize Terlipressin compare norepinephrine would decrease mortality among patient septic shock .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Septic shock define presence two diagnostic criterion systemic inflammatory responsesyndrome , proven suspected infection , hypotension ( exclusion hypertention sepsis ) organ transplantation ; pregancy breastfeeding ; malignancy irreversible disease condition poor prognosis ; acute coronary syndrome ; chronic heart failure ( NYHA III IV ) /cardiogenic shock ; acute mesenteric ischemia ; great 48 hour elapse since patient meet entry criterion ; estimation incomplite treament due financial problem ; use terlipressin blood pressure support entry ; Raynaud 's phenomenon , systemic sclerosis vasospastic diathesis ; registration clinical trial affect outcome current study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>